Clinical Trial Management - software & AI news

Daily news on software, AI, and companies shaping clinical trial management.

Showing 35 results
Map pin symbolizing community practices in cancer treatment

May 8, 2026

Caris Life Sciences (Nasdaq:CAI) - Stock Analysis

Caris Life Sciences is addressing the significant access gap in cancer clinical trials with its innovative Right-In-Time (RIT) solution, aimed at expanding the reach of precision oncology to community practices across the U.S.The urgency to bridge the geographic divide in cancer trial access is underscored by research indicating that 70% of U.S. counties lack active cancer treatment trials. This limitation affects nearly 20% of older Americans, who do not have local options for investigational t
A heart on a scale representing clinical trials in cardiology.

May 8, 2026

Iterative Health raises $77 mn in Series C funding to expand AI-driven trial network

Iterative Health has successfully secured $77 million in Series C funding to enhance its AI-powered clinical trial network, aiming to broaden its research focus beyond gastroenterology and hepatology into cardiology and obesity.The funding round, led by Intrepid Growth Partners and GV, also saw participation from EDBI and existing investors like Insight Partners. This capital will support the company's international expansion and address challenges in clinical trials, which are often hindered by
A clinical trial document on a desk in a research office

May 7, 2026

Taimei Technology And C&R Research Partner To Advance AI Driven Clinical Trial Operations In South Korea

Taimei Technology and C&R Research have entered a strategic partnership aimed at revolutionizing clinical trial operations in South Korea through AI-driven solutions.This collaboration will leverage Taimei's advanced AI capabilities and digital infrastructure to streamline clinical trial processes. C&R Research plans to implement Taimei's AI Agents to enhance trial design and operational workflows, particularly focusing on data management through innovative tools such as intelligent data capture
Silhouettes of gemcitabine and nab-paclitaxel molecules on a solid background

May 7, 2026

Polaris AI Pharma Rises on News of FDA Approval and Expanded Pancreatic Cancer Clinical Scope for Investee 'Alpha Tau'

Polaris AI Pharma is experiencing a notable increase in stock value, attributed to recent FDA approval granted to its investee, Alpha Tau Medical, for an expanded clinical focus on pancreatic cancer.On May 7, Polaris AI Pharma's shares rose by 5.01%, reaching 7,330 won following the announcement that Alpha Tau Medical has received supplemental FDA approval. This allows Alpha Tau to broaden its clinical trial scope for pancreatic cancer, specifically through the addition of a gemcitabine/nab-pacl
An implantable brain-computer interface on a surgical tray in a dimly lit clinical setting.

May 3, 2026

Axoft Bags $55M Series A Funding to Advance Clinical Trials Globally for its Implantable Brain-Computer Interface

Axoft, a neurotechnology firm based in Cambridge, Massachusetts, has successfully secured $55 million in a Series A funding round led by C.P. Group Innovation, with participation from notable investors including Alumni Ventures, the Stanford President’s Venture Fund, Hillhouse Investment, and Gaorong Ventures. This brings the company's total funding to over $60 million.The newly acquired funds will primarily support Axoft in expanding its clinical trials globally and advancing the regulatory app
A clinical trial participant reviewing a medical chart in a research facility.

May 2, 2026

Iterative Health Secures $77M to Expand AI-driven Clinical Research Tech

Iterative Health has successfully raised $77 million to enhance its AI-powered clinical research platform, aiming to broaden its therapeutic focus into cardiology and obesity.The Massachusetts-based healthtech company plans to utilize this funding to improve trial recruitment and expand its existing capabilities in gastroenterology and hepatology. With a network that includes over 100 research sites across four continents and partnerships with more than 40 stakeholders—ranging from biotech compa
A glass vial on a lab bench with a microscope in the background

Apr 30, 2026

AI in Clinical Development Summit to Showcase Life Sciences and Technology Leaders Driving Real-World AI Impact

The upcoming AI in Clinical Development Summit aims to unite leaders in life sciences and technology to discuss the real-world applications of AI in clinical trials.Scheduled for May 27, 2026, in New York City, the summit will feature prominent figures from major pharmaceutical companies such as AstraZeneca, Bristol Myers Squibb, Sanofi, and Roche, alongside technology experts from firms like Accenture and AWS. The event will include a range of activities, including expert panels, fireside chats
A clinical trial site with a patient consent form on a table and researchers in the background.

Apr 30, 2026

Clinical trial timelines in flux: Considerations for U.S. and UK biopharma companies

Recent trends show a significant shift in clinical trial locations, particularly for U.S. and UK biopharma companies, as they increasingly turn to overseas sites, especially in China, to expedite trial timelines.The FDA's acceptance of foreign clinical data has led to a growing number of trials being conducted outside the U.S., with over 50% of registered clinical trials as of February being based solely overseas. This is a stark contrast to the 29% of trials conducted exclusively within the U.S
A minimalist illustration of a pill on a dark background, symbolizing drug development.

Apr 29, 2026

FDA’s AI Push Ignites a new Biotech Arms Race and Totaligent may be quietly Positioning Itself at the Center

The FDA's recent embrace of artificial intelligence (AI) is transforming the landscape of biotech, signaling a shift from traditional drug development to a more integrated, technology-driven approach. This regulatory momentum is particularly relevant for companies like Totaligent, which are positioning themselves to capitalize on the efficiencies AI can bring to clinical trials and commercialization.The FDA is actively promoting AI as a core component of drug development, aiming to streamline cl
A clinical trial consent form and pen on a wooden table

Apr 25, 2026

EU privacy regulators adopt a single data-processing lawful basis for clinical trials

European data protection authorities have expressed support for the proposed European Biotech Act while emphasizing the need for robust protections for health data in clinical trials.The European Data Protection Board (EDPB) and the European Data Protection Supervisor (EDPS) have issued Joint Opinion 3/2026, which endorses the objectives of the European Biotech Act aimed at enhancing the EU's biotechnology sector. However, they caution that regulatory simplification should not compromise the rig
A minimalist illustration of a test tube and data chart in a dark color scheme.

Apr 25, 2026

Thermo Fisher Raises Outlook As Clario Deal Deepens AI Trial Capabilities

Thermo Fisher Scientific has finalized its acquisition of Clario, enhancing its capabilities in clinical trial technology and AI-driven research.This strategic move has led Thermo Fisher to revise its revenue and earnings per share forecasts upward, reflecting anticipated contributions from Clario. The integration of Clario's advanced tools is expected to significantly benefit biopharma clients by improving trial efficiency and data quality, particularly as the industry increasingly focuses on t